Special Issue

Recent Advances in Nanomedicine for Cancer Therapy

Message from the Guest Editors

This Special Issue of Pharmaceutics welcomes contributions that deal with all aspects of nanomedicine for cancer research, including:

Inorganic nanoparticles for drug delivery and cancer therapeutics.

Immunomodulating nanomedicine for cancer.

Organic nanomaterials such as polymeric micelles, dendrimers and proteins for cancer application.

Autophagy modulation using cancer nanomedicine.

Nanomedicine-based synergistic

therapy/photothermal therapy.

Future prospectives of nanomedicine.

Guest Editors

Dr. Batakrishna Jana

Department of Chemistry, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Korea

Dr. Kibeom Kim

Convergence Research Center, Nanobiomaterials Institute, Sahmyook University, Seoul 01795, Korea

Deadline for manuscript submissions

closed (20 May 2024)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/136686

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

